Efficacy and Safety of Combination 308-nm Excimer Laser and Intralesional Corticosteroid versus Intralesional Corticosteroid Monotherapy in the Treatment of Frontal Fibrosing Alopecia: A Pilot Study

Rattapon  Thuangtong; Supisara Wongdama; Nuttagarn Jantanapornchai; Chadakan Yan; Kanchalit Thanomkitti; Daranporn Triwongwaranat

doi:10.33192/smj.v75i11.265185

Efficacy and Safety of Combination 308-nm Excimer Laser and Intralesional Corticosteroid versus Intralesional Corticosteroid Monotherapy in the Treatment of Frontal Fibrosing Alopecia: A Pilot Study

Authors

Rattapon Thuangtong Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Supisara Wongdama Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Nuttagarn Jantanapornchai Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Chadakan Yan Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Kanchalit Thanomkitti Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand
Daranporn Triwongwaranat Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

DOI:

https://doi.org/10.33192/smj.v75i11.265185

Keywords:

excimer laser, intralesional corticosteroid, frontal fibrosing alopecia, lichen planopilaris

Abstract

Frontal fibrosing alopecia (FFA) is a slowly progressive cicatricial alopecia that can result in permanent hair loss, so early diagnosis and treatment is crucial. However and of concern, a standard treatment regimen for FFA has not yet been established. In an attempt to remedy this gap, we conducted this study to investigate the efficacy and safety of combined 308-nm excimer laser with intralesional corticosteroid (ILC) compared to ILC alone to treat FFA. The results of our study revealed that the combination of 308-nm excimer laser and ILC was not superior to ILC alone for treating FFA. Moreover, side effects, including erythema and postinflammatory hyperpigmentation, were reported in both groups.

References

To D, Beecker J. Frontal Fibrosing Alopecia: Update and Review of Challenges and Successes. J Cutan Med Surg. 2018;22(2):182-9.

Holmes S, Ryan T, Young D, Harries M, Hair B, Society N. Frontal Fibrosing Alopecia Severity Index (FFASI): a validated scoring system for assessing frontal fibrosing alopecia. Br J Dermatol. 2016;175(1):203-7.

Fertig R, Tosti A. Frontal fibrosing alopecia treatment options. Intractable Rare Dis Res. 2016;5(4):314-5.

Zhang M, Zhang L, Rosman IS, Mann CM. Frontal fibrosing alopecia demographics: a survey of 29 patients. Cutis. 2019;103(2):E16-E22.

Navarini AA, Kolios AG, Prinz-Vavricka BM, Haug S, Trueb RM. Low-dose excimer 308-nm laser for treatment of lichen planopilaris. Arch Dermatol. 2011;147(11):1325-6.

FFA patient who was rated as minimal improvement on both sides by dermatologists

Downloads

Published

01-11-2023

How to Cite

Thuangtong , R. ., Wongdama, S., Jantanapornchai, N., Yan, C., Thanomkitti, K., & Triwongwaranat, D. (2023). Efficacy and Safety of Combination 308-nm Excimer Laser and Intralesional Corticosteroid versus Intralesional Corticosteroid Monotherapy in the Treatment of Frontal Fibrosing Alopecia: A Pilot Study. Siriraj Medical Journal, 75(11), 835–837. https://doi.org/10.33192/smj.v75i11.265185

Download Citation

Issue

Vol. 75 No. 11 (2023): November

Section

Letter to the Editor

License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following conditions:

Copyright Transfer

In submitting a manuscript, the authors acknowledge that the work will become the copyrighted property of Siriraj Medical Journal upon publication.

License

Articles are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). This license allows for the sharing of the work for non-commercial purposes with proper attribution to the authors and the journal. However, it does not permit modifications or the creation of derivative works.

Sharing and Access

Authors are encouraged to share their article on their personal or institutional websites and through other non-commercial platforms. Doing so can increase readership and citations.